"Interleukin-17" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proinflammatory cytokine produced primarily by T-LYMPHOCYTES or their precursors. Several subtypes of interleukin-17 have been identified, each of which is a product of a unique gene.
Descriptor ID |
D020381
|
MeSH Number(s) |
D12.644.276.374.465.517 D12.776.467.374.465.517 D23.529.374.465.517
|
Concept/Terms |
Interleukin-17F- Interleukin-17F
- Interleukin 17F
- IL-17F
- Cytokine ML-1
- Cytokine ML 1
Interleukin-17C- Interleukin-17C
- Interleukin 17C
- IL-17C
- Cytokine CX2
- CX2, Cytokine
Interleukin-17E- Interleukin-17E
- Interleukin 17E
- Interleukin-25
- Interleukin 25
- IL-17E
- IL 17E
Interleukin-17A- Interleukin-17A
- Interleukin 17A
- Cytotoxic T lymphocyte-Associated Antigen 8
- Cytotoxic T lymphocyte Associated Antigen 8
- IL-17A
- CTLA8
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-17".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-17".
This graph shows the total number of publications written about "Interleukin-17" by people in this website by year, and whether "Interleukin-17" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2005 | 3 | 0 | 3 |
2006 | 1 | 1 | 2 |
2007 | 3 | 2 | 5 |
2008 | 6 | 4 | 10 |
2009 | 12 | 5 | 17 |
2010 | 8 | 3 | 11 |
2011 | 8 | 4 | 12 |
2012 | 5 | 4 | 9 |
2013 | 0 | 5 | 5 |
2014 | 5 | 4 | 9 |
2015 | 4 | 3 | 7 |
2016 | 3 | 9 | 12 |
2017 | 2 | 9 | 11 |
2018 | 7 | 3 | 10 |
2019 | 4 | 1 | 5 |
2020 | 2 | 2 | 4 |
2021 | 3 | 1 | 4 |
2022 | 0 | 1 | 1 |
2023 | 1 | 4 | 5 |
2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-17" by people in Profiles.
-
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
-
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open. 2024 Aug 30; 10(3).
-
Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia. Am J Pathol. 2024 Nov; 194(11):2023-2035.
-
Downregulation of Mirlet7 miRNA family promotes Tc17 differentiation and emphysema via de-repression of ROR?t. Elife. 2024 May 09; 13.
-
Th17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment. Pediatr Rheumatol Online J. 2024 Mar 02; 22(1):32.
-
Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. Cancer Cell. 2024 01 08; 42(1):85-100.e6.
-
Gut Inflammation in Axial Spondyloarthritis Patients is Characterized by a Marked Type 17 Skewed Mucosal Innate-like T Cell Signature. Arthritis Rheumatol. 2023 11; 75(11):1969-1982.
-
Gut microbiota aggravates neutrophil extracellular traps-induced pancreatic injury in hypertriglyceridemic pancreatitis. Nat Commun. 2023 10 04; 14(1):6179.
-
ROR?t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating ?d-T cells. Rheumatology (Oxford). 2023 09 01; 62(9):3169-3178.
-
Obstructive Sleep Apnea-Induced Hypertension Is Associated With Increased Gut and Neuroinflammation. J Am Heart Assoc. 2023 06 06; 12(11):e029218.